Skip to main content
Contact Us
Subscribe
E-Edition
82°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acelyrin Inc
(NQ:
SLRN
)
4.780
-0.030 (-0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Acelyrin Inc
< Previous
1
2
Next >
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
August 20, 2024
Via
Benzinga
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
August 14, 2024
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab.
Via
Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
August 14, 2024
Via
Benzinga
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
August 13, 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 08, 2024
Via
Benzinga
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
May 15, 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
March 28, 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
March 20, 2024
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half...
Via
Benzinga
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
March 11, 2024
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show...
Via
Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
December 17, 2023
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now.
Via
InvestorPlace
What 5 Analyst Ratings Have To Say About Acelyrin
November 28, 2023
Via
Benzinga
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Via
Benzinga
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
November 28, 2023
Acelyrin Inc (NASDAQ: SLRN) updated its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in
Via
Benzinga
Acelyrin (SLRN) Q3 2023 Earnings Call Transcript
November 07, 2023
SLRN earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
September 30, 2023
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars.
Via
InvestorPlace
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Why Acelyrin Stock Plummeted 59% This Week
September 15, 2023
The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate.
Via
The Motley Fool
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 13, 2023
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of...
Via
Benzinga
Despite Trial Setback For Acelyrin's Lead Program, Analyst Shows Optimism
September 12, 2023
Acelyrin Inc (NASDAQ: SLRN) announced topline results from Part B of a Phase 2b/3 trial evaluating izokibep for moderate-to-severe Hidradenitis Suppurativa (HS).
Via
Benzinga
Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
September 12, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded up 0.11% to 34,702.55 while the NASDAQ fell 0.86% to 13,797.73....
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
September 13, 2023
Via
Benzinga
Dow Turns Higher; Oracle Shares Tumble After Q1 Results
September 12, 2023
U.S. stocks traded mixed midway through trading, with the Dow Jones turning higher on Tuesday. The Dow traded up 0.22% to 34,740.15 while the NASDAQ fell 0.55% to 13,841.02. The S&P 500, also fell,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
September 12, 2023
A competitor's clinical trial stumble may be benefiting MoonLake.
Via
The Motley Fool
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
September 12, 2023
Benzinga
Via
Benzinga
Is American Battery Technology Company (ABML) Stock Really Up 1,300%?
September 12, 2023
American Battery Technology Company (ABML) stock surprised investors Tuesday morning when it appeared to rocketing more than 1,300% higher.
Via
InvestorPlace
Dow Falls 75 Points; US Small Business Optimism Drops In August
September 12, 2023
U.S. stocks traded lower this morning, with the Dow Jones falling around 75 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.22% to 34,587.58 while the NASDAQ fell 0.21%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Datasea (DTSS) Stock Down 39% Today?
September 12, 2023
Datasea (DTSS) stock is falling on Tuesday after the company announced a proposed public stock offering priced at 40 cents per share.
Via
InvestorPlace
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%
September 12, 2023
The companies are both working on treatments for a rare skin disease.
Via
Investor's Business Daily
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.